GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Otonomy Inc (OTCPK:OTIC) » Definitions » Debt-to-Equity

Otonomy (Otonomy) Debt-to-Equity : 1.43 (As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Otonomy Debt-to-Equity?

Otonomy's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $19.66 Mil. Otonomy's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $10.88 Mil. Otonomy's Total Stockholders Equity for the quarter that ended in Sep. 2022 was $21.40 Mil. Otonomy's debt to equity for the quarter that ended in Sep. 2022 was 1.43.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Otonomy's Debt-to-Equity or its related term are showing as below:

OTIC's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.15
* Ranked among companies with meaningful Debt-to-Equity only.

Otonomy Debt-to-Equity Historical Data

The historical data trend for Otonomy's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Otonomy Debt-to-Equity Chart

Otonomy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.19 0.84 0.49 0.58

Otonomy Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.58 0.73 0.97 1.43

Competitive Comparison of Otonomy's Debt-to-Equity

For the Biotechnology subindustry, Otonomy's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Otonomy's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Otonomy's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Otonomy's Debt-to-Equity falls into.



Otonomy Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Otonomy's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Otonomy's Debt to Equity Ratio for the quarter that ended in Sep. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Otonomy  (OTCPK:OTIC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Otonomy Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Otonomy's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Otonomy (Otonomy) Business Description

Traded in Other Exchanges
N/A
Address
4796 Executive Drive, San Diego, CA, USA, 92121
Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity primarily operates through the region of the United States.
Executives
Hogan H Michael Iii director C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Alan Charles Foster officer: Chief Scientific Officer 4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121
Savel Robert Michael Ii officer: Chief Technical Officer 1025 OPAL WAY, VACAVILLE CA 95687
Paul E Cayer officer: CFO/Ch. Business Offcr & Sec. C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
David Allen Weber director, officer: President & CEO C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
Jill Marie Broadfoot director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jay Lichter director C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Ciara Kennedy director C/O LUMENA PHARMACEUTICALS, INC., 12531 HIGH BLUFF DRIVE, SUITE 110, SAN DIEGO CA 92130
James B Breitmeyer director
Eric J Loumeau officer: GC & Chief Compliance Officer C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Katherine Mary Bishop officer: Chief Scientific Officer C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121
Carl Lebel officer: Chief Scientific Officer 23256 MARIPOSA DE ORO, MALIBU CA 90265
Iain Mcgill director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Chau Quang Khuong director C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022